
Rigel Pharmaceuticals (RIGL) surpassed EPS estimates by 18.5% for its 2022 third quarter. Moreover, the U.S. Food and Drug Administration approved its REZLIDHIA (olutasidenib) capsules for treating adult patients with relapsed or refractory (R/R) acute myeloid leukemia. REZLIDHIA is expected to be incredibly beneficial for patients with poor prognoses and is a solid addition to RIGL’s product portfolio.
RIGL shares soared on the news. They have gained 30.2% over the past month. However, RIGL has lost 67.1% year-to-date and 64.9% over the past year to close the last trading session at $0.87.